Literature DB >> 2310654

A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man.

M D Nielsen1, K Brøsen, L F Gram.   

Abstract

1. Twelve healthy extensive metabolisers of sparteine were sparteine tested daily for 6 days (19.00 h to 07.00 h). A small but statistically significant rise in sparteine metabolic ratio (MR) was observed. 2. Following 100 mg quinidine sulphate given to four of the subjects at 16.00 h, sparteine tests were carried out 19.00 h to 07.00 h on the same day and then daily for 6 days. Quinidine caused an immediate twenty-fold increase in sparteine-MR which then gradually returned to normal over the following 4-6 days. Quinidine concentrations in plasma were measurable only up to 20 h after the quinidine test dose. 3. At weekly intervals, all 12 subjects received single doses of quinidine sulphate of 5, 10, 20, 40 and 80 mg at 16.00 h, each time followed by a sparteine test 19.00 h to 07.00 h on the same day. A clear dose-effect relationship was found with a significant rise in the sparteine-MR even after 5 mg quinidine. After 80 mg quinidine, 8 of 12 subjects became phenotypically poor metabolisers (MR greater than 20).

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2310654      PMCID: PMC1380129          DOI: 10.1111/j.1365-2125.1990.tb03639.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  29 in total

1.  Inhibition of desipramine 2-hydroxylation by quinidine and quinine.

Authors:  E Steiner; E Dumont; E Spina; R Dahlqvist
Journal:  Clin Pharmacol Ther       Date:  1988-05       Impact factor: 6.875

2.  Clinical significance of the sparteine/debrisoquine oxidation polymorphism.

Authors:  K Brøsen; L F Gram
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

3.  Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo.

Authors:  T Inaba; R E Tyndale; W A Mahon
Journal:  Br J Clin Pharmacol       Date:  1986-08       Impact factor: 4.335

4.  Pharmacokinetics and metabolism of quinidine in extensive and poor metabolisers of sparteine.

Authors:  G Mikus; H R Ha; S Vozeh; C Zekorn; F Follath; M Eichelbaum
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

5.  Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man.

Authors:  U M Zanger; F Vilbois; J P Hardwick; U A Meyer
Journal:  Biochemistry       Date:  1988-07-26       Impact factor: 3.162

6.  Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.

Authors:  C J Speirs; S Murray; A R Boobis; C E Seddon; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

7.  Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment.

Authors:  K Brøsen; L F Gram; T Haghfelt; L Bertilsson
Journal:  Pharmacol Toxicol       Date:  1987-04

8.  In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver.

Authors:  S V Otton; R U Brinn; L F Gram
Journal:  Drug Metab Dispos       Date:  1988 Jan-Feb       Impact factor: 3.922

9.  Sparteine oxidation is practically abolished in quinidine-treated patients.

Authors:  R Brinn; K Brøsen; L F Gram; T Haghfelt; S V Otton
Journal:  Br J Clin Pharmacol       Date:  1986-08       Impact factor: 4.335

10.  Characterization of the common genetic defect in humans deficient in debrisoquine metabolism.

Authors:  F J Gonzalez; R C Skoda; S Kimura; M Umeno; U M Zanger; D W Nebert; H V Gelboin; J P Hardwick; U A Meyer
Journal:  Nature       Date:  1988-02-04       Impact factor: 49.962

View more
  14 in total

1.  Pharmacokinetic profile of dextromethorphan hydrobromide in a syrup formulation in children and adolescents.

Authors:  Eric Guenin; Marianna Armogida; Dennis Riff
Journal:  Clin Drug Investig       Date:  2014-09       Impact factor: 2.859

2.  An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems.

Authors:  R C Halliday; B C Jones; D A Smith; N R Kitteringham; B K Park
Journal:  Br J Clin Pharmacol       Date:  1995-10       Impact factor: 4.335

3.  Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes.

Authors:  P Dalén; M Dahl; K Andersson; L Bertilsson
Journal:  Br J Clin Pharmacol       Date:  2000-02       Impact factor: 4.335

4.  Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition.

Authors:  A A Moghadamnia; A Rostami-Hodjegan; R Abdul-Manap; C E Wright; A H Morice; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

5.  Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Danish University Antidepressant Group.

Authors:  L F Gram; K Brøsen
Journal:  Br J Clin Pharmacol       Date:  1993-06       Impact factor: 4.335

Review 6.  Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.

Authors:  T Andersson
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

7.  Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone.

Authors:  D Wu; S V Otton; B A Sproule; U Busto; T Inaba; W Kalow; E M Sellers
Journal:  Br J Clin Pharmacol       Date:  1993-01       Impact factor: 4.335

8.  Quinidine but not quinine inhibits in man the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase.

Authors:  G Muralidharan; E M Hawes; G McKay; E D Korchinski; K K Midha
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

9.  The effect of a low dose of quinidine on the disposition of flecainide in healthy volunteers.

Authors:  A Munafo; T Buclin; D Tuto; J Biollaz
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

10.  In vitro forecasting of drugs that may interfere with codeine bioactivation.

Authors:  P Dayer; J Desmeules; R Striberni
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Apr-Jun       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.